{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T05:10:10Z","timestamp":1743138610108,"version":"3.40.3"},"reference-count":18,"publisher":"American Society of Consultant Pharmacists","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:p><jats:bold>Background<\/jats:bold> Vibegron, a beta<jats:sub>3<\/jats:sub>-adrenergic receptor agonist for overactive bladder, can be administered as an intact tablet or crushed and mixed with applesauce for patients with dysphagia.  <jats:bold>Objectives<\/jats:bold> To evaluate the suitability of crushed vibegron\n for administration via enteral feeding tubes.  <jats:bold>Methods<\/jats:bold> Vibegron 75 mg tablets were crushed, suspended in 15 mL water, and delivered through seven commonly used enteral tubes. Minimum required flush volume was assessed by flushing with 10, 20, or 30 mL water and quantifying\n dose delivery using high-performance liquid chromatography (HPLC). Material compatibility was assessed by holding doses in each tube for 5, 15, and 30 minutes and using HPLC to quantify dose delivery and detect impurities in vibegron and control (vibegron tablet) samples. Dosing repeatability\n was assessed by delivering six replicates through each tube and quantifying dose delivery. Tube occlusion was evaluated visually in all assays. Mean dose delivery through each tube was assessed using pooled data and analyzed by ANOVA.  <jats:bold>Results<\/jats:bold> Delivery of &gt; 90% was achieved\n in all assays, for all tubes assessed, with \u2265 20 mL flush volume; 5-, 15-, or 30-minute hold times; and delivery of 1 to 6 doses through the same tube. No additional impurities were detected in vibegron samples compared with controls. Tube occlusion was not observed. Mean dose delivery\n was &gt; 95% for all tubes assessed and not significantly different between tubes (F = 1.02; <jats:italic>P<\/jats:italic> = 0.4).  <jats:bold>Conclusions<\/jats:bold> Crushed vibegron tablets dispersed in 15 mL of water were delivered consistently and completely through a variety of enteral tubes with no evidence\n of material incompatibility or clogging.<\/jats:p>","DOI":"10.4140\/tcp.n.2025.185","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T04:36:22Z","timestamp":1742963782000},"page":"185-193","source":"Crossref","is-referenced-by-count":0,"title":["Suitability of Crushed Vibegron 75 mg Tablets for Enteral Administration"],"prefix":"10.4140","volume":"40","author":[{"given":"Jennifer","family":"Woo","sequence":"first","affiliation":[{"name":"1 Sumitomo Pharma America, Inc., Marlborough, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Washington","sequence":"additional","affiliation":[{"name":"1 Sumitomo Pharma America, Inc., Marlborough, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothy","family":"Aikin","sequence":"additional","affiliation":[{"name":"1 Sumitomo Pharma America, Inc., Marlborough, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca Briggs","family":"Colamarino","sequence":"additional","affiliation":[{"name":"1 Sumitomo Pharma America, Inc., Marlborough, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad","family":"Worz","sequence":"additional","affiliation":[{"name":"2 American Society of Consultant Pharmacists, Alexandria, Virginia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laleh","family":"Abedinzadeh","sequence":"additional","affiliation":[{"name":"1 Sumitomo Pharma America, Inc., Marlborough, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003985","article-title":"The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder.","volume":"212","year":"2024","journal-title":"J Urol."},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","article-title":"National community prevalence of overactive bladder in the United States stratified by sex and age.","volume":"77","year":"2011","journal-title":"Urology."},{"issue":"36","key":"ref3","first-page":"1","article-title":"Prevalence of incontinence among older Americans.","volume":"3","year":"2014","journal-title":"Vital Health Stat."},{"issue":"9","key":"ref4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4140\/TCP.n.2015.533","article-title":"Clinical burden and nonpharmacologic management of nursing facility residents with overactive bladder and\/or urinary incontinence.","volume":"30","year":"2015","journal-title":"Consult Pharm."},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1177\/000348940711601112","article-title":"Dysphagia in the elderly: preliminary evidence of prevalence, risk factors, and socioemotional effects.","volume":"116","year":"2007","journal-title":"Ann Otol Rhinol Laryngol."},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/nmo.12467","article-title":"Prevalence and risk factors for dysphagia: a USA community study.","volume":"27","year":"2015","journal-title":"Neurogastroenterol Motil."},{"issue":"10","key":"ref7","first-page":"895907","article-title":"Crushed tablet administration for patients with dysphagia and enteral feeding: challenges and considerations.","volume":"40","year":"2023","journal-title":"Drugs Aging."},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"21955","DOI":"10.1038\/s41598-021-99858-w","article-title":"Prevalence of oropharyngeal dysphagia in geriatric patients and real-life associations with diseases and drugs.","volume":"11","year":"2021","journal-title":"Sci Rep."},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/0148607108330314","article-title":"Enteral nutrition practice recommendations.","volume":"33","year":"2009","journal-title":"JPEN J Parenter Enteral Nutr."},{"volume-title":"Full Prescribing Information","year":"2023","key":"ref10"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/cpdd.1169","article-title":"Pharmacokinetics and safety of vibegron 75 mg administered as an intact or crushed tablet in healthy adults.","volume":"11","year":"2022","journal-title":"Clin Pharmacol Drug Dev."},{"year":"2021","key":"ref12","article-title":"Oral drug products administered via enteral feeding tube: in vitro testing and labeling recommendations"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1208\/s12248-024-00896-9","article-title":"Oral drug product administration via enteral feeding tubes: in vitro testing","volume":"26","year":"2024","journal-title":"AAPS J."},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/jpen.2490","article-title":"Developing guidance for feeding tube administration of oral medications.","volume":"47","year":"2023","journal-title":"JPEN J Parenter Enteral Nutr."},{"issue":"17","key":"ref15","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1111\/j.1365-2702.2008.02407.x","article-title":"A systematic review of nursing administration of medication via enteral tubes in adults.","volume":"17","year":"2008","journal-title":"J Clin Nurs."},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/0148607109337257","article-title":"Warfarin bioavailability with feeding tubes and enteral formula","volume":"34","year":"2010","journal-title":"JPEN J Parenter Enteral Nutr."},{"volume-title":"Handbook of Drug Administration via Enteral Feeding Tubes.","year":"2015","key":"ref17"},{"issue":"24","key":"ref18","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.2146\/ajhp080155","volume":"65","year":"2008","journal-title":"Am J Health Syst Pharm."}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2025\/00000040\/00000004\/art00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T04:35:56Z","timestamp":1743136556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2025.185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"alternative-id":["2639-9636(20250401)40:4L.185;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2025.185","relation":{},"ISSN":["2639-9636"],"issn-type":[{"type":"print","value":"2639-9636"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}